Author(s): Sinai Talaulikar V, Tang T, Yasmin E
Abstract Share this page
Abstract IMPORTANCE: Metformin, an oral antihyperglycemic drug, acts as an insulin sensitizer in the treatment of type 2 diabetes mellitus. It has also been widely used in the treatment of polycystic ovary syndrome (PCOS) and gestational diabetes mellitus. Although randomized clinical trials have failed to establish its superiority over other forms of treatment, metformin continues to be a treatment option in specific subgroups of women either alone or as an adjunct with other therapies in management of PCOS. OBJECTIVE AND EVIDENCE ACQUISITION: This narrative review was conducted to assess the present role of metformin in management of clinical conditions related to women's health. A PubMed search was conducted using the following terms: "metformin," "polycystic," "ovary," "Women's," "health," "gestational," "diabetes," "cancer," and "fertility," and all relevant studies were evaluated for accumulation of evidence. RESULTS AND CONCLUSIONS: Metformin is used as a second-line drug for ovulation induction in women with PCOS who are resistant to clomiphene citrate. Metformin also forms one of the management options in women who need antiandrogen therapy without the need for contraception at the same time. Women with PCOS undergoing in vitro fertilization are likely to benefit from metformin therapy to reduce their risk of ovarian hyperstimulation syndrome. Metformin alone or in combination with insulin has been reported to have similar safety and efficacy to insulin for the treatment of GDM. There is growing evidence that metformin may be associated with a decreased risk of developing cancers and improved response to chemotherapy.
This article was published in Obstet Gynecol Surv
and referenced in Vitamins & Minerals